- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Daxor Corporation(DXR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DXR
11/13/2026: DXR (1-star) is currently NOT-A-BUY. Pass it for now.
Daxor Corporation is a micro-cap medical technology company specializing in blood volume measurement through its flagship BVA-100 analyzer and proprietary disposable kits. The company's primary strength lies in its unique, FDA-cleared diagnostic niche and razor-and-blades recurring revenue model. Its main investment opportunity centers on scaling hospital network adoption and expanding ezBVA Lab testing services to address costly fluid management issues. However, the company faces substantial execution risks, high share price volatility, and intense competition from entrenched medical device giants. Daxor suits speculative or momentum-oriented investors willing to monitor hospital contract wins and cash-flow milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the micro-cap addressable market is large, high execution risk makes future growth uncertain. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp upside moves on positive clinical adoption news or capital raising announcements. |
| Value investor | Weak fit | Traditional valuation metrics are difficult to apply given early-stage commercial revenues and lack of steady earnings. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing all capital on commercialization and product development. |
| Low-risk investor | Weak fit | High share price volatility and micro-cap liquidity risks make it unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Low trading liquidity and micro-cap status result in sharp price fluctuations. |
| Valuation risk | Medium / high | Valuation is often disconnected from traditional earnings multiples, relying heavily on future potential. |
| Competition risk (large medtech incumbents) | High | Well-capitalized medical device giants dominate hospital procurement channels and clinical mindshare. |
| Business quality | Medium | Proprietary FDA-cleared technology provides a regulatory moat, but commercial scaling remains unproven. |
| Dividend income | Low / none | No dividend is paid to investors. |
| Execution risk | High | Success depends entirely on convincing conservative hospital networks to adopt a specialized diagnostic workflow. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.51M USD | Price to earnings Ratio 7.71 | 1Y Target Price 20 |
Price to earnings Ratio 7.71 | 1Y Target Price 20 | ||
Volume (30-day avg) 12.4K shares | Beta 0.44 | 52 Weeks Range 8.24 - 14.76 | Updated Date 11/15/2026 |
52 Weeks Range 8.24 - 14.76 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.1 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.7%
- Active BUY / eligible
- 69 / 110
- 30-Day BUY Count Change
- +30
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 60.0%
- Active BUY / eligible
- 3 / 5
- 30-Day BUY Count Change
- +1
Eligible universe: 5 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -41.67% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Medical Instrumentation | Placements and sales of the BVA-100 Blood Volume Analyzer system to hospitals and clinical laboratories. | Selling or placing the core diagnostic hardware machine inside healthcare facilities. |
| Diagnostic Consumables | Proprietary single-use Volumex radiopharmaceutical kits required for every individual test performed. | A razor-and-blades recurring revenue stream generated every time a blood volume test is run. |
| Laboratory Testing Services | Outsourced blood volume analysis performed via the company's CLIA-certified laboratory. | Providing direct diagnostic testing services to client hospitals without local machine installation. |
Valuation
Trailing PE 7.71 | Forward PE 64.52 | Enterprise Value 42.93M | Price to Sales(TTM) 1578.7 |
Enterprise Value 42.93M | Price to Sales(TTM) 1578.7 | ||
Enterprise Value to Revenue 6.07 | Enterprise Value to EBITDA - | Shares Outstanding 5.84M | Shares Floating 2.90M |
Shares Outstanding 5.84M | Shares Floating 2.90M | ||
Percent Insiders 49.5 | Percent Institutions 7.87 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

